threebabiesbusy
5年前
https://finance.yahoo.com/news/wpd-pharmaceuticals-licensor-announces-100-123000433.html
WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug
MBRX
Moleculin Biotech, Inc.
Add to Watchlist
4.7600
+0.0800 (+1.71%)
At close: 4:00PM EST
5.0000 +0.2400 (+5.042%)
Before hours: February 5 8:57AM EST
NasdaqGS - Nasdaq Real Time Price. Currency in USD
View quote details
Related stories
Simply Wall St.
What You Need To Know About Moleculin Biotech, Inc.'s (NASDAQ:MBRX) Investor Composition
1d ago
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute...Yahoo Finance
Related Quotes
More content below
More content below
MBRX
+1.71%
WPDPF
-1.17%
WPD Pharmaceuticals
Fri, February 5, 2021, 6:30 AM
More content below
More content below
MBRX
+1.71%
WPDPF
-1.17%
Potentially significant therapeutic benefit against metastatic, Annamycin shown to reach "sanctuary sites" of cancer
VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that that Moleculin Biotech Inc. (NASDAQ:MBRX) (“Moleculin”), the company that sublicenses the compound Annamycin to WPD for 29 countries mainly in Europe, announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. The Moleculin press release of February 2, 2020 states, “This appears to be the result of the high cytotoxic potential of Annamycin previously demonstrated in vitro against sarcoma cells in combination with its high uptake by the lungs where the tumors in this study are localized. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals.
Osteosarcoma is among a class of tumors that initiate in the bone of patients, with bone-related sarcomas representing the second most common form of sarcoma after soft tissue sarcoma. While many bone sarcomas can be addressed through surgical removal, it is estimated that as many as 40% of bone sarcomas will eventually metastasize to the lungs, where treatment can become more problematic. Researchers have more recently referred to the lungs and certain other vital organs as "sanctuary sites" for cancer where tumors can develop out of reach from conventional chemotherapies.
Once metastasized to the lungs, if tumors cannot be surgically removed, the primary chemotherapy regimen is the anthracycline doxorubicin (also known as Adriamycin). While 10% to 30% of patients with sarcoma lung metastases may initially respond to doxorubicin, most will relapse leaving the majority of these patients without an alternative chemotherapy. Moleculin recently announced findings from its sponsored research showing that doxorubicin has a limited ability to accumulate in the lungs of animals, which may help explain its limited efficacy in this sanctuary site. Treatment options are further limited because of the inherent cardiotoxicity of currently approved anthracyclines, including doxorubicin, which limits the amount of anthracycline that can be given to patients.
Money $hot
5年前
@money$hot: Thanks but die you read this?
But you are right, it is too early to talk about it. It is a bet on the future, right?
Nascent should combine its drug with WP1122 from WPD Pharmaceuticals to stop this covid19 virus.
CNS + WPD Pharmaceuticals could really help us out of this fu**ing Covid19 life!
Covid19-drug-news: REVIVE could easily cooperate with WPD Pharma, who also develop a Covid19-drug called WP1122. Did you read this?
Just wondering: AVEO could easily buy WPD Pharma, who develop a Covid19-drug called WP1122. Did you read this?
Merck could easily buy WPD Pharma, who develop a Covid19-drug called WP1122. Did you read this?
Pfizer + WPD Pharma? Covid19-drug-news coming soon!? Pfizer + WPD Pharma could rule the world smile Is WP1122 really the only Covid19-drug in the world?
B I N G O - I full stopped reading there^
M$
jejusk
6年前
?
CSE: WBIO
WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101
Vancouver, British Columbia – Sept 16, 2020 – WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has received a prepayment of approximately C$705,000 (2,000,000 PLN) and approval for reimbursement of approximately C$175,000 (500,000 PLN) from the Polish National Center for Research and Development (“NCRD”) granted by the European Union, under the Smart Growth Operational Program 2014-2020, for the further development of WPD101, the Company’s drug candidate targeting glioblastoma (“GBM”) which includes Phase I clinical studies.
The NCRD is an executive agency of the Minister of Science and Higher Education. It was established as a unit implementing tasks in the field of science, technology, and state innovation policy. The main aim of the Centre is to support the creation of innovative solutions and technologies that increase the competitiveness and innovation of the Polish economy. The approved prepayment for WPD’s continued advancements of the WPD101 drug candidate further validates its scientific development strategy and government support in doing so.
WPD is developing WPD101 which will allow GMB patients access to innovative molecular targeted therapies as an alternative to conventional treatment. The drug is currently in preclinical development and its consistent anticancer properties are demonstrated and validated in dogs with spontaneous GBM closely resembling GBM in human patients.
Overall, the results of these studies indicate the significant potential of WPD101 demonstrating the same effective treatment of GBM in humans. The Company expects Phase I clinical trials to begin in 2021.
Mariusz Olejniczak, CEO of WPD Pharmaceuticals commented, “We are very pleased to receive this second prepayment from the grant issued by the NCRD, which continues to validate our progress and development plans of WPD101. This funding provides important cashflow support and will be used for further development and upcoming Phase I clinical trials. Approval of these prepayments requires diligent work and I am proud of the project management team for their continued efforts.”
About WPD Pharmaceuticals
WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in the clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing, and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.
On Behalf of the Board
‘Mariusz Olejniczak’
Mariusz Olejniczak
CEO, WDP Pharmaceuticals
Contact:
Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com
Cautionary Statements:
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that we can access the remainder of our NCRD grant and that WPD’s drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs don’t provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.
WPD Pharmaceuticals sp. z o.o.
Zwirki i Wigury 101, 02-089 Warszawa, Polska
NIP: 5252721500, KRS: 0000693186
tel: +48 515 262 381
Email: info@wpdpharmaceuticals.com
Click here to unsubscribe from this list or email info@wpdpharmaceuticals.com indicating you wish to be unsubscribed.
?
makinezmoney
6年前
$WPDPF: Used to be $WCOTF..........
MBRX news today using WP1122........ POSITIVE FOR Covid19
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
7:46 AM ET 7/21/20 | Dow Jones
Related Quotes
4:00 PM ET 7/20/20
Symbol Last % Chg
MBRX
1.10 0.00%
Real time quote.
Shares of small-cap Moleculin Biotech Inc. soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing confirmed antiviral activity for WP1122, its candidate as a treatment for COVID-19. The lab involved was IIT Research Institute, an affiliate of the Illinois Institute of Technology, which conducted additional in vitro testing of the drug candidate. The testing involved a cell viability assay in the VERO E6 cell line infected with the coronavirus that causes COVID-19 and compared the therapeutic effects of 2-DG (the active ingredient in WP1122) alone with those of WP1122, a 2-DG prodrug.The result is very preliminary; based on feedback from the FDA, Moleculin expects it will need to show activity in a COVID-19 animal model to successfully submit a request for Investigational New Drug ("IND") status for WP1122. The company is testing other compounds in its portfolio as treatments for COVID-19. Shares have gained 20% in the year to date,
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
> Dow Jones Newswires
July 21, 2020 07:46 ET (11:46 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GO $WPDPF
jejusk
6年前
NEWS!!
WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate
Vancouver, British Columbia – May 28, 2020 – WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that on May 21, 2020 Wake Forest University received a patent from the United States Patent and Trademark Office (“USPTO”) for a patent titled “EphA3 and Multi-Valent Targeting of Tumors” (under application number 15/958,608). The patent is exclusively licensed to WPD, and the patent relates to the WPD101 drug candidate, used in the therapy of glioblastoma multiform (“GBM”).
Mariusz Olejniczak, CEO of WPD commented, “We are very excited to receive another patent included in the license agreement with Wake Forest University. This patent covers EPHA3 and multi-valent targeting of tumors and provides an additional layer of protection for our IP in the development of drug candidate WPD101. It is especially helpful for the development of our glioma product but also for other tumor fighting drugs we are developing.”
Cancer cells, including GBM tumor cells that are highly resistant to all known therapies, express tumor specific receptors, IL-13RA2 and EphA2. WPD Pharmaceuticals’ patented solution is based on the use of therapy targeting IL-13RA2 and EphA2 receptors by
genetically modified IL-13 and Ephrin1 proteins, conjugated to Pseudomonas and Diphtheria bacteria toxins. Recombinant IL-13 and Ephrin1 proteins armed with potent bacteria toxins preferentially bind to GBM tumor-specific receptors and deliver highly cytotoxic payload. This highly specific targeting of GBM cells should allow for selective elimination of tumor cells by bacteria-toxins-induced cytotoxic effects without affecting normal cells. In order to move to Phase 1 clinical trials in humans, WPD will need to finish the manufacturing for the development of the drug delivery formulation, expected to be completed within approximately one year.
Within the WP 101,102,103 portfolio of drug candidates, WPD and its licensors have 40 patents issued or filed in key territories including the US, Canada, and EU.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Renee
6年前
メールアドレスで登録
